Bone Therapeutics is a leading cell therapy company addressing high unmet medical needs in the field of orthopaedics and bone diseases. The Company is bringing a unique value proposition by developing a new treatment approach using differentiated bone-forming cells administrated via a minimally invasive procedure. It has a broad and diversified portfolio of product candidates in clinical development across a number of orthopaedics area: impaired fracture healing, spinal fusion, and osteonecrosis.
Our primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for hip osteonecrosis.
In addition, Bone Therapeutics is conducting preclinical research on next generation products. Our cell therapy products are manufactured to the highest GMP standards and are protected by a rich Intellectual Property estate covering nine patent families.